Pharma News

Keep updating your pharma knowledge
30 Dec 2020

Glenmark introducing Remogliflozin + Vildagliptin combination first time in India

Glenmark Pharmaceuticals Limited is introducing a fixed dose combination (FDC) of Remogliflozin + Vildagliptin.

Remogliflozin is Sodium Glucose Co-Transporter Inhibitor (SGLT2i).

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, greatly improve the quality of life of patients, and reduce medical expenses for families and society.

Vildagliptin is DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor).

The fixed drug combination is indicated for the management of Type 2 diabetes.

The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed dose combination and India is the first country to get access to this new fixed dose combination in India. Glenmark received approval from the DCGI (the drug approval authority in India) for manufacturing and marketing Remogliflozin + Vildagliptin combination in late November 2020.

Pricing positioning

This fixed dose combination will be providing lot of pricing advantage. Diabetes drugs should be taken for long time and therefore pricing is definitely plays a vital role. Moreover, India is price conscious market.

As mentioned by Glenmark – “While the average daily cost of therapy of existing brands in the same drug category is Rs. 78, Glenmark’s Remogliflozin-Vildagiptin combination has been launched at a breakthrough price of Rs. 14 per tablet, to be taken twice daily; which amounts to Rs. 28 as the per day cost of therapy. This cost is 65% lower than the other available SGLT2 & DPP4 combination drugs in the market.”

pharma product management course by royed training

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!